Сare pathways of children with acute rhinological symptoms

Acute respiratory diseases are one of the most common reasons for visiting a doctor in pediatric practice. Most episodes of this pathology have a viral etiology, signs of inflammation from the upper respiratory tract and proceed with symptoms of acute rhinitis (acute nasopharyngitis). The most of episodes of acute rhinitis last no more than 10 days and end with the patient’s recovery. The most common complications of acute rhinitis in children are acute rhinosinusitis and acute otitis media. These diseases are often mild and rarely have complications. However, a large number of patients with acute respiratory diseases increases the likelihood of a situation in which the doctor will encounter a problem patient. The article proposes care pathways for practitioners to manage patients with acute rhinological symptoms lasting up to 10 days and from 10 days to 3 months. The care pathways are based on several key points. No1: each patient must be analyzed for the presence of alarming symptoms, upon detection of which the patient should be urgently hospitalized. No2: all patients should be dynamically observed by a doctor until complete recovery, the patient should not receive treatment without the supervision of a doctor. No3: the basis of treatment is drugs for symptomatic therapy, which are selected depending on the dominant symptom that has the greatest impact on the patient’s well-being. To eliminate nasal mucosal edema, it is rational to use nasal decongestants (original oxymetazoline) for children of all ages; the course and dosages are determined according to the age of the child. Antibacterial drugs should be prescribed strictly according to indications in the presence of convincing data for the bacterial etiology of the disease.

1. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S. et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58(Suppl 29):1–464. https://doi.org/10.4193/Rhin20.600.

2. Dykewicz M.S., Wallace D.V., Amrol D.J., Baroody F.M., Bernstein J.A., Craig T.J. et al. Rhinitis 2020: A Practice Parameter Update. J Allergy Clin Immunol. 2020;146(4):721–767. https://doi.org/10.1016/j.jaci.2020.07.007.

3. Smith M.M., Ishman S.L. Pediatric Nasal Obstruction. Otolaryngol Clin North Am. 2018;51(5):971–985. https://doi.org/10.1016/j.otc.2018.05.005.

4. Baranov A.A., Lobzin Yu.V., Namazova- Baranova L.S., Tatochenko V.K., Uskov A.N., Kulichenko T.V. et al. Acute Respiratory Viral Infection (ARVI): Clinical Guidelines (Draft). Moscow; 2020. 25 p. (In Russ.) Available at: https://www.pediatr- russia.ru/information/klin-rek/proekty-klinicheskikhrekomendatsiy/ОРВИ%20дети%20СПР.v1_2019%20-%20финал.pdf.

5. Ryazantsev S.V., Karneeva O.V., Garashchenko T.I., Gurov A.V., Svistushkin V.M., Sapova K.I. et al. Acute Sinusitis: Clinical Guidelines. Moscow: Ministry of Health of the Russian Federation; 2016. 30 p. (In Russ.) Available at: http://www.nmaoru.org/files/KR313%20Ostryj%20sinusit.pdf.

6. Karneeva O.V., Polyakov D.P., Gurov A.V., Ryazantsev S.V., Maksimova E.A., Kazanova A.V. Otitis Media Acute: Clinical Guidelines. Moscow: Ministry of Health of the Russian Federation; 2016. 24 p. (In Russ.) Available at: http://www.nmaoru.org/files/KR314%20Ostryj%20srednij%20otit.pdf.

7. Villwock J.A., Kuppersmith R.B. Diagnostic Algorithm for Evaluating Nasal Airway Obstruction. Otolaryngol Clin North Am. 2018;51(5):867–872. https://doi.org/10.1016/j.otc.2018.05.002.

8. Tulupov D.A., Fedotov F.A., Karpova E.P., Grabovskaya V.A. Current Aspects of Use of Nasal Vasoconstrictors and Adjunctive Agents in Pediatric Practice. Meditsinskiy sovet = Medical Council. 2018;(2):114–117. (In Russ.) https://doi.org/10.21518/2079-701X-2018-2-114-117.

9. Andersson K.E., Bende M. Adrenoreceptors in the Control of Human Nasal Mucosal Blood Flow. Ann Otol Rhinol Laryngol. 1984;93(2 Pt 1):179–182. https://doi.org/10.1177/000348948409300216.

10. Varvyanskaya A.V., Lopatin A.S. Topical Nasal Decongestants: Comparative Charac ter istics and a Review of Side Effects. Rossiyskaya rinologiya = Russian Rhinology. 2015;23(4):50–56. (In Russ.) https://doi.org/10.17116/rosrino201523450-56.

11. Johannssen V., Maune S., Werner J.A., Rudert H., Ziegler A. Alpha 1-Receptors at Pre- Capillary Resistance Vessels of the Human Nasal Mucosa. Rhinology. 1997;35(4):161–165. Available at: https://www.rhinologyjournal.com/Rhinology_issues/223.pdf.

12. Haenisch B., Walstab J., Herberhold S., Bootz F., Tschaikin M., Ramseger R., Bönisch H. Alpha- Adrenoceptor Agonistic Activity of Oxymetazoline and Xylometazoline. Fundam Clin Pharmacol. 2010;24(6):729–739. https://doi.org/10.1111/j.1472-8206.2009.00805.x.

13. Koelsch S., Tschaikin M., Sacher F. Anti-rhinovirus-specific activity of the alpha-sympathomimetic oxymetazoline. Arzneimittelforschung. 2007;57(7):475–482. https://doi.org/10.1055/s-0031-1296635.

14. Beck-Speier I., Oswald B., Maier K.L., Karg E., Ramseger R. Oxymetazoline inhibits and resolves inflammatory reactions in human neutrophils. J Pharmacol Sci. 2009;110(3):276–284. https://doi.org/10.1254/jphs.09012fp.

15. Druce H.M., Ramsey D.L., Karnati S., Carr A.N. Topical Nasal Decongestant Oxymetazoline (0.05%) Provides Relief of Nasal Symptoms for 12 Hours. Rhinology. 2018;56(4):343–350. https://doi.org/10.4193/Rhin17.150.

16. Karpova E.P., Tulupov D.A., Vorob’eva M.P., Fedotov F.A., Dolginov D.M., Bykov M.V., Grabovskaya V.A. About the safety of application of nasal decongestants in the practice of pediatricians. Vestnik otorinolaringologii = Bulletin of Otorhinolaryngology. 2018;83(2):46–50. (In Russ.) https://doi.org/10.17116/otorino201883246-50.

17. Astafieva N.G., Baranov A.A., Vishneva E.A., Daykhes N.A., Zhestkov A.V., Ilyina N.I. et al. Allergic Rhinitis: Clinical Guidelines. Moscow; 2020. 84 p. (In Russ.) Available at: https://raaci.ru/dat/pdf/allergic_rhinitis.pdf.